Hers vs Ro: Program Models, Medication, and Pricing Compared

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx holds no commercial relationship with Hers, with Ro, or with either company’s parent organization, and no affiliate links or compensation are involved.

Shoppers weighing Hers against Ro are usually comparing two subscription telehealth brands that both operate in the GLP-1 and weight-management space. This review looks at how each program is built, how their medication and pricing models differ, and the one metabolic variable that sits outside both platforms. As of April 2026 the telehealth GLP-1 market spans dozens of providers; this piece stays focused on the two named in the query.

How Hers structures its program

Hers is the women’s brand under Hims & Hers Health and runs as subscription telehealth. Programs in this model generally bundle a virtual clinical evaluation, provider-issued prescriptions, and either brand-name FDA-approved GLP-1 dispensing or compounded semaglutide/tirzepatide through licensed compounding-pharmacy pathways. Current program specifics live on Hers’s official website.

How Ro structures its program

Ro (Roman Health) is also a subscription telehealth service, and its medication menu, membership tiers, and pricing shift over time. Rather than rely on a figure that may be stale by the time you read this, confirm the current structure on Ro’s official website.

The medication and mechanism are the same

Here is the part both brands share: the pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) act on appetite regulation, satiety signaling, and gastric emptying identically regardless of which platform delivers them. What differs between Hers and Ro is the business model — the dispensing pathway (brand-name vs compounded), the degree of provider oversight, and the price. The molecule does the work; the brand is the packaging around it.

Comparing price and access

GLP-1 telehealth pricing ranges widely across the market as of April 2026, with typical monthly totals landing somewhere around $200–$700+ once program fees, medication, and compounded dispensing are added together. Each brand publishes its own numbers, so the reliable move is to open both pricing pages side by side before committing rather than trusting a third-party figure that ages quickly.

What the evidence says about the underlying class

Whichever brand you choose, the clinical evidence belongs to the compound, not the storefront. GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry a deep trial record: STEP studied semaglutide for weight management (NEJM 2021), SURMOUNT studied tirzepatide for weight management (NEJM 2022), and SURMOUNT-OSA studied tirzepatide for obstructive sleep apnea (NEJM 2024). Effect sizes shift with compound, dose, and population — but a program’s results are driven by the molecule it prescribes, not the brand name on the invoice.

The variable neither Hers nor Ro maps

What no telehealth intake captures is the genetic architecture underneath your GLP-1 response. Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor itself — the target of every compound in this class), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) describe the metabolic terrain a clinician is prescribing into. These are pathway-level markers: they do not predict how you will respond to any single compound, but they frame the biology a prescription alone leaves unexamined.

PlexusDx offers semaglutide and tirzepatide inside its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — but pairs the protocol with something the telehealth brands skip. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, MC4R, and TCF7L2 variants that shape your baseline appetite-regulation and energy-balance biology. That is the test before you invest idea: turn guesswork into an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Hers or Ro and has no commercial relationship with the companies reviewed here.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Ro and has no commercial relationship with the companies reviewed; it offers semaglutide and tirzepatide through its own Weight Management Protocols, and this piece compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach directly: review the Weight Management Protocols, or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway before you subscribe anywhere.

Frequently Asked Questions

Are Hers and Ro the same type of service?

Both are subscription telehealth brands operating in the GLP-1 weight-management space, so their overall structure is similar. Where they diverge is the specific medication menu, membership tiers, provider model, and published pricing. Individual fit comes down to cost, coverage, and program mechanics rather than one being categorically different.

Does one offer better GLP-1 medication than the other?

Neither platform changes the underlying pharmacology. Both can prescribe GLP-1 receptor agonists through telehealth, and the compound itself drives the biological effect. Differences fall in the dispensing pathway, brand-name versus compounded options, and the subscription terms, not in the drug’s mechanism of action.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

It does not predict how you will respond to Hers, Ro, or any specific compound. Instead it analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 biology — the upstream context that applies across every GLP-1 program regardless of which brand delivers it.

Where does PlexusDx fit against Hers and Ro?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, then adds genetic context via the Precision Peptide Genetic Test. The differentiator is pathway-level insight mapping FTO, MC4R variants — the metabolic groundwork most GLP-1 telehealth programs, Hers and Ro included, do not address.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education